Marvin White - EMERGENT BIOSOLUT Director
ER4 Stock | EUR 9.54 0.09 0.95% |
Insider
Marvin White is Director of EMERGENT BIOSOLUT since 2020.
Age | 53 |
Tenure | 4 years |
Marvin White Latest Insider Activity
Tracking and analyzing the buying and selling activities of Marvin White against EMERGENT BIOSOLUT stock is an integral part of due diligence when investing in EMERGENT BIOSOLUT. Marvin White insider activity provides valuable insight into whether EMERGENT BIOSOLUT is net buyers or sellers over its current business cycle. Note, EMERGENT BIOSOLUT insiders must abide by specific rules, including filing SEC forms every time they buy or sell EMERGENT BIOSOLUT'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Marvin White over three months ago Acquisition by Marvin White of 9584 shares of Aptevo Therapeutics at 0.001 subject to Rule 16b-3 | ||
Marvin White over six months ago Disposition of 9584 shares by Marvin White of Aptevo Therapeutics subject to Rule 16b-3 | ||
Marvin White over six months ago Disposition of 12917 shares by Marvin White of Aptevo Therapeutics subject to Rule 16b-3 | ||
Marvin White over a year ago Exercise or conversion by Marvin White of 7200 shares of Emergent Biosolutions subject to Rule 16b-3 |
Similar Executives
Found 10 records | INSIDER Age | ||
Frans Heerden | Astral Foods Limited | 42 | |
Christiaan Schutte | Astral Foods Limited | 63 | |
Michael Schmitz | Astral Foods Limited | 62 | |
Louis Vermaas | Astral Foods Limited | 51 | |
Agric MBA | Astral Foods Limited | 50 | |
Gideon Jordaan | Astral Foods Limited | 49 | |
Colin Smith | Astral Foods Limited | 62 | |
Leonie Marupen | Astral Foods Limited | 51 | |
Evert Potgieter | Astral Foods Limited | 53 | |
Bcompt Bcom | Astral Foods Limited | 67 |
EMERGENT BIOSOLUT Leadership Team
Elected by the shareholders, the EMERGENT BIOSOLUT's board of directors comprises two types of representatives: EMERGENT BIOSOLUT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EMERGENT. The board's role is to monitor EMERGENT BIOSOLUT's management team and ensure that shareholders' interests are well served. EMERGENT BIOSOLUT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EMERGENT BIOSOLUT's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
Sean Kirk, Executive Vice President Manufacturing and Technical Operations | ||
Katherine Strei, Executive Vice President, Human Resources and Communications, Chief Human Resources Officer | ||
Fuad ElHibri, Executive Chairman of the Board | ||
Sue Bailey, Independent Director | ||
Jerome Hauer, Independent Director | ||
Marvin White, Director | ||
Kathryn Zoon, Independent Director | ||
Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
Seamus Mulligan, Director | ||
George Joulwan, Independent Director | ||
Adam Havey, Executive Vice President and Presidentident - BioDefense Division | ||
Louis Sullivan, Independent Director | ||
Ronald Richard, Lead Independent Director | ||
Zsolt Harsanyi, Independent Director | ||
Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
EMERGENT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EMERGENT BIOSOLUT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Current Valuation | 1.34 B | |||
Price To Book | 0.43 X | |||
Price To Sales | 0.42 X | |||
Revenue | 1.12 B | |||
EBITDA | (41.1 M) | |||
Net Income | (223.8 M) | |||
Total Debt | 448.5 M | |||
Cash Flow From Operations | (34.1 M) | |||
Number Of Employees | 18 | |||
Market Capitalization | 1.91 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.